Program
Warfarin
Also written as “warfarin”, “ZT002 injection, metformin, warfarin” and “Warfarin sodium”.
Its studies are mostly in Obesity · Venous Thrombosis · Diabetes Mellitus, Type 2 · Urinary Bladder, Overactive · Liver Cirrhosis, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 50 open or running | phase 1since May 18, 2009 | May 18, 2009 | none ahead |
| Boehringer Ingelheim | 40 open or running | phase 3since Dec 6, 2005 | Dec 6, 2005 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since Jul 21, 2011 | Jul 21, 2011 | none ahead |
| Kowa | 10 open or running | phase 4since Aug 9, 2010 | Aug 9, 2010 | none ahead |
Also a collaborator on its studies: Eli Lilly, Bayer, Bristol-Myers Squibb and Valerio Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 6, 2005First study: phase 3 study in Atrial FibrillationNew to Boehringer IngelheimBoehringer Ingelheim · NCT00262600 · 18,113 enrolled · United States, Argentina, Australia and more
- May 18, 2009AstraZeneca's first study: phase 1 study in Diabetes Mellitus, Type 2New to AstraZenecaAstraZeneca · NCT00904176 · 30 enrolled · United States
- Apr 26, 2010Phase 1 study in HealthyBoehringer Ingelheim · NCT01111331 · 18 enrolled · Germany
- Aug 9, 2010Kowa's first study: phase 4 study in HealthyNew to KowaKowa · NCT01178853 · 48 enrolled · United States
- Sep 21, 2010Phase 1 study in PharmacokineticsAstraZeneca · NCT01214122 · Sweden
- Feb 21, 2011Phase 1 study in Arthritis, RheumatoidAstraZeneca · NCT01311622 · 15 enrolled · United Kingdom
- Jul 21, 2011Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT01400646 · 46 enrolled · Belgium
- Sep 8, 2011Phase 1 study in HypertriglyceridemiaAstraZeneca · NCT01431690 · 52 enrolled · United States
- Jan 20, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02345304 · Germany
- Sep 2, 2015Phase 1 study in HealthyAstraZeneca · NCT02540668 · 15 enrolled · United States
- Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741385 · 4 enrolled · Germany
TargetBeta
“Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor; Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor”ChEMBL 37, by rule
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05741385Liver Cirrhosis · Germany | – | Completed | Boehringer Ingelheim | Aug 9, 2024 | 4 |
| NCT02540668Healthy · United States | 1 | Completed | AstraZeneca | Jan 31, 2016 | 15 |
| NCT02345304Healthy · Germany | 1 | Withdrawn | Boehringer Ingelheim | Apr 2015 | 0 |
| NCT01431690Hypertriglyceridemia · United States | 1 | Completed | AstraZeneca | Oct 2011 | 52 |
| NCT01400646Healthy · Belgium | 1 | Completed | Johnson & Johnson | May 2012 | 46 |
| NCT01311622Arthritis, Rheumatoid · United Kingdom | 1 | Completed | AstraZeneca | May 2011 | 15 |
| NCT01214122Pharmacokinetics · Sweden | 1 | Withdrawn | AstraZeneca | Dec 2010 | 0 |
| NCT01178853Healthy · United States | 4 | Completed | Kowa | Oct 2010 | 48 |
| NCT01111331Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2010 | 18 |
| NCT00904176Diabetes Mellitus, Type 2 · United States | 1 | Completed | AstraZeneca | Aug 2009 | 30 |
| NCT00262600Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Apr 2009 | 18,113 |
How it is read
Names in the registry
- “Warfarin”, 20 entries
- “warfarin”, 7 entries
- “ZT002 injection, metformin, warfarin”, 1 entry
- “Warfarin sodium”, 1 entry
- “Drug Cocktail”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Venous Thrombosis, 2 studies
- Diabetes Mellitus, Type 2, 2 studies
- Urinary Bladder, Overactive, 2 studies
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.